CTX-M-33 is a CTX-M-15 derivative conferring reduced susceptibility to carbapenems

18Citations
Citations of this article
46Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

CTX-M-type extended-spectrum β-lactamases (ESBLs) are widespread among Enterobacterales strains worldwide. The most common variant is CTX-M-15, which hydrolyzes ceftazidime at a high rate but spares carbapenems. Here, we identified CTX-M-33, a point mutation derivative of CTX-M-15 (Asp to Ser substitution at Ambler position 109) that exhibited low carbapenemase activity. β-Lactamase CTX-M-33 was identified in a Klebsiella pneumoniae isolate, belonging to sequence type 405 and lacking the outer membrane protein OmpK36, that was resistant to broad-spectrum cephalosporins and β-lactam/β-lactamase inhibitor combinations and displayed decreased susceptibility to carbapenems. Comparative hydrolytic activity assays showed that CTX-M-33 hydrolyzed ceftazidime at a lower level than CTX-M-15 but significantly hydrolyzed meropenem. In addition, CTX-M-33 showed higher mutant prevention concentration values and a wider mutant selection window in the presence of meropenem, in accordance with its observed hydrolytic properties. Here, we identified the very first CTX-M enzyme possessing weak carbapenemase activity, which may correspond to an emerging phenomenon, considering its possible evolution from the widespread ESBL CTX-M-15.

Cite

CITATION STYLE

APA

Poirel, L., de la Rosa, J. M. O., Richard, A., Aires-De-Sousa, M., & Nordmann, P. (2019). CTX-M-33 is a CTX-M-15 derivative conferring reduced susceptibility to carbapenems. Antimicrobial Agents and Chemotherapy, 63(12). https://doi.org/10.1128/AAC.01515-19

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free